Journal of Cardiothoracic Surgery | |
Severe non-traumatic bleeding events detected by computed tomography: do anticoagulants and antiplatelet agents have a role? | |
Kasra Azarnoush3  Lionel Camilleri2  Louis Boyer1  Anderson H Amani2  Aurelien Mulliez4  Agaicha Alfidja1  Olivier Risch1  | |
[1] pôle Imagerie et Radiologie Interventionnelle CHU de Clermont-Ferrand, ISIT, UMR CNRS 6284 - université d¿Auvergne Clermont Hospital, Clermont-Ferrand, France;Heart surgery Department, G. Montpied Hospital, Clermont-Ferrand University Hospital, Clermont-Ferrand 63000, France;INRA, UMR 1019 Nutrition Humaine, Saint Genès Champanelle, France;Bio-statistics unit, Délégation Recherche Clinique & Innovation, Clermont-Ferrand University Hospital, Clermont-Ferrand, France | |
关键词: CT-scan; Antiplatelet agents; Anticoagulant; Muscular hematoma; Intracranial hemorrhage; | |
Others : 1151743 DOI : 10.1186/s13019-014-0166-9 |
|
received in 2014-06-18, accepted in 2014-09-26, 发布年份 2014 | |
【 摘 要 】
Purpose
Bleeding is the most common and most serious complication of anticoagulant (AC) and antiplatelet agents (APA) which are increasingly used in every day practice. The aim of this study was to enlist and analyze the most severe bleeding events revealed during computed tomography scanner (CT scan) examinations over a 1-year period at our University Hospital and to evaluate the role of ACs and APAs in their occurrence.
Methods
This descriptive monocentric retrospective study included all patients who benefited from an emergency CT scan with a diagnosis of severe non-traumatic bleeding. Patients were divided into two groups: those treated with ACs and/or APAs, and those not treated with ACs or APAs.
Results
After applying the inclusion criteria, 93 patients were enrolled. Sixty-one patients received an anticoagulant or antiplatelet treatment, and 32 did not receive any AC or APA therapy. Seventy nine percent presented with an intracranial hemorrhage, 17% with a rectus sheath or iliopsoas bleeding or hematoma, and 4% with a quadriceps hematoma. Only patients who received ACs or APAs suffered a muscular hematoma (p <0.0001). Among patients treated with vitamin K antagonists, 6/43 (14%), had an international normalized ratio (INR) higher than the therapeutic range (INR >3).
Conclusions
In our series, intracranial hemorrhage was preponderant and muscular hematomas occurred exclusively in patients treated with ACs and/or APAs. This study needs to be extended to evaluate the impact of new anticoagulant and antiplatelet agents.
【 授权许可】
2014 Risch et al.; licensee BioMed Central Ltd.
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
20150406102842370.pdf | 1508KB | download | |
Figure 3. | 32KB | Image | download |
Figure 2. | 28KB | Image | download |
Figure 1. | 31KB | Image | download |
【 图 表 】
Figure 1.
Figure 2.
Figure 3.
【 参考文献 】
- [1]Dunning J, Versteegh M, Fabbri A, Pavie A, Kolh P, Lockowandt U, Nashef SA: Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur J Cardiothorac Surg 2008, 34:73-92.
- [2]Gras-Champel V, Brenet-Dufour V, Moragny J, Masson H, Davidau E, Masmoudi K, Andrejak M: Quantification of the part allocated to the preventability of vitamin K antagonists therapy bleeding events. Therapie 2010, 65:261-268.
- [3]Pouyanne P, Haramburu F, Imbs JL, Bégaud B: Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. French Pharmacovigilance Centres. BMJ 2000, 320:1036.
- [4]Lansberg MG, O¿Donnell MJ, Khatri P, Lang ES, Nguyen-Huynh MN, Schwartz NE, Sonnenberg FA, Schulman S, Vandvik PO, Spencer FA, Alonso-Coello P, Guyatt GH, Akl EA: American College of Chest Physicians. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141:e601S-36S.
- [5]Cosserat F, Colnat-Coulbois S, Klein O, Audibert G, Petitpain N, Tréchot P, Auque J: Hémorragies intracrâniennes et anticoagulants oraux: étude des facteurs pronostiques à partir d¿une série de 186 cas. Neurochirurgie 2009, 55S:11-16.
- [6]Grillo P, Velly L, Bruder N: Accident vasculaire cérébral hémorragique: nouveautés sur la prise en charge. Ann Fr Anesth Reanim 2006, 25:868-873.
- [7]Poli D, Antonucci E, Testa S, Tosetto A, Ageno W, Palareti G: Result of a prospective collaborative study on elderly patients followed by Italian centres for anticoagulation. Circulation 2011, 124:824-829.
- [8]Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L: Dabigatran versus Warfarin in Patients with Atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
- [9]Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365:883-91.
- [10]Claudot F, Alla F, Fresson J, Calvez T, Coudane H, Bonaïti-Pellié C: Ethics and observational studies in medical research: various rules in a common framework. Int J Epidemiol 2009, 38(4):1104-1108.
- [11]Azarnoush K, Camilleri L, Aublet-Cuvelier B, Geoffroy E, Dauphin C, Dubray C, De Riberolles C: Results of the first randomized French study evaluating self-testing of the International Normalized Ratio. J Heart Valve Dis 2011, 20:518-525.
- [12]Coppens M, Eikelboom JW, Hart RG, Yusuf S, Lip GY, Dorian P, Shestakovska O, Connolly SJ: The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. Eur Heart J 2013, 34:170-176.
- [13]Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D¿Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S: Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996, 348:423-428.
- [14]Cucchiara B, Messe S, Sansing L, Kasner S, Lyden P: Hematoma Growth in Oral Anticoagulant Related Intracerebral Hemorrhage. Stroke 2008, 11:2993-2996.
- [15]Tonolini M, Ippolito S, Patella F, Petullà M, Bianco R: Hemorrhagic complications of anticoagulant therapy: role of multidetector computed tomography and spectrum of imaging findings from head to toe. Curr Probl Diagn Radiol 2012, 41:233-247.
- [16]Bauersachs RM: Use of anticoagulants in elderly patients. Thromb Res 2012, 129:107-115.
- [17]Butchart EG, Payne N, Li HH, Buchan K, Mandana K, Grunkemeier GL: Better anticoagulation control improves survival after valve replacement. J Thorac Cardiovasc Surg 2002, 123:715-723.
- [18]Azarnoush K, Dorigo E, Pereira B, Dauphin C, Geoffroy E, Dauphin N, D¿Ostrevy N, Legault B, Camilleri L: Mid-term results of self-testing of the international normalized ratio in adults with a mechanical heart valve. Thromb Res 2013, ?:?. Sep 16. In press
- [19]Van Walraven C, Oake N, Wells PS, Forster AJ: Burden of potentially avoidable anticoagulant-associated hemorrhagic and thromboembolic events in the elderly. Chest 2007, 131:1508-1515.
- [20]Feldmann E, Broderick JP, Kernan WN, Viscoli CM, Brass LM, Brott T, Morgenstern LB, Wilterdink JL, Horwitz RI: Major risk factors for intracerebral hemorrhage in the young are modifiable. Stroke 2005, 36:1881-1885.
- [21]Brott T, Thalinger K, Hertzberg V: Hypertension as a risk factor for spontaneous intracerebral hemorrhage. Stroke 1986, 17:1078-1083.